Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial
Year: 2016
Type: article
Source: Annals of Oncology
Authors: G.D. Demetri, P. Reichardt, Y.-K. Kang, J.-Y. Blay, H. Joensuu, C. Kappeler, C. Wuchter-Czerwony, J. Chung, A. Wagner, P.G. Casali
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Helios Hospital Berlin-Buch, Asan Medical Center, University of Ulsan, Centre Léon Bérard, Helsinki University Hospital, Bayer (Germany), Bayer (United States), Fondazione IRCCS Istituto Nazionale dei Tumori
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2589010686